Q3 EPS Forecast for Prelude Therapeutics Boosted by Analyst

Key Points

• HC Wainwright raised Prelude Therapeutics’ Q3 2026 EPS forecast to a loss of $0.13 per share from its previous estimate of $0.16, while maintaining a “Buy” rating and $8 price target.
• Analyst sentiment is mixed but leans positive: five analysts rate the stock “Buy,” one “Hold,” and one “Sell,” producing a consensus “Moderate Buy” rating and average price target of $8.75.
• Prelude shares opened at $3.32, well below the analyst consensus target, while institutional investors own approximately 79.72% of the company; BlackRock recently established a roughly $9.6 million position.

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) - Investment analysts at HC Wainwright raised their Q3 2026 earnings estimates for Prelude Therapeutics in a research note issued to investors on Tuesday, October 13th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.13) for the quarter, up from their prior estimate of ($0.16). HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for Prelude Therapeutics' current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Prelude Therapeutics' Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.54) EPS and FY2027 earnings at ($0.67) EPS.

PRLD has been the topic of a number of other reports. Wall Street Zen lowered Prelude Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, September 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Prelude Therapeutics in a report on Wednesday, July 29th. JPMorgan Chase & Co. initiated coverage on Prelude Therapeutics in a research report on Thursday, September 17th. They issued an "overweight" rating and a $12.00 price target for the company. Finally, Citigroup reiterated a "market outperform" rating on shares of Prelude Therapeutics in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $8.75.

Prelude Therapeutics Stock Performance

Shares of NASDAQ:PRLD opened at $3.32 on Friday. The company has a market capitalization of $264.94 million, a PE ratio of -4.55 and a beta of 0.97. The stock has a fifty day moving average of $4.86 and a 200-day moving average of $4.53. Prelude Therapeutics has a one year low of $1.16 and a one year high of $6.83.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.06. The business had revenue of $5.70 million during the quarter, compared to analyst estimates of $5.70 million.

Institutional Investors Weigh In On Prelude Therapeutics

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Prelude Therapeutics in the 2nd quarter valued at approximately $9,581,000. EcoR1 Capital LLC purchased a new position in Prelude Therapeutics during the 1st quarter worth approximately $3,239,000. ADAR1 Capital Management LLC purchased a new position in Prelude Therapeutics during the 2nd quarter worth approximately $4,802,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Prelude Therapeutics during the 2nd quarter valued at $669,000. Finally, Bank of New York Mellon Corp acquired a new stake in Prelude Therapeutics during the 2nd quarter valued at $363,000. Institutional investors and hedge funds own 79.72% of the company's stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company uses cancer biology, medicinal chemistry and targeted drug-discovery approaches to identify small-molecule therapies designed to address genetic and molecular vulnerabilities in tumors.

Prelude's investigational pipeline has included PRT3789, a selective SMARCA2 protein degrader being developed for cancers with SMARCA4 loss, and PRT2527, a selective cyclin-dependent kinase 9 (CDK9) inhibitor under evaluation for oncology applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.